Life sciences company Ananda Developments PLC (AQSE: ANA) announced on Wednesday that it has contracted Southern Star Research Pty Ltd, an Australian Contract Research Organisation, to conduct a Phase 1 clinical trial for its lead investigative asset, MRX1.
This study will assess the pharmacokinetic (PK) profile, tolerability and safety of MRX1 in 20 healthy volunteers.
To be conducted in Australia, the trial will generate crucial data for future regulatory applications with agencies such as the MHRA and FDA.
The decision to conduct the study in Australia provides financial benefits, including a 43.5% R&D tax incentive.
This trial is a key step in advancing MRX1, an oral drug candidate aimed at treating complex inflammatory pain conditions, with Phase 2 trials planned for chemotherapy-induced peripheral neuropathy and endometriosis.
EMA accepts marketing application for Alvotech's AVT03
Capricor begins BLA submission for deramiocel in Duchenne muscular dystrophy
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Biogen receives FDA Breakthrough Therapy Designation for felzartamab
Inspira Technologies develops new disposable kit for perfusion market
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics